SUMOylation-triggered ALIX activation modulates extracellular vesicles circTLCD4-RWDD3 to promote lymphatic metastasis of non-small cell lung cancer [0.03%]
SUMO化触发的ALIX激活调控细胞外囊泡circTLCD4-RWDD3促进非小细胞肺癌淋巴转移
Xiayao Diao,Chao Guo,Hanhao Zheng et al.
Xiayao Diao et al.
Lymph node (LN) metastasis is one of the predominant metastatic routes of non-small cell lung cancer (NSCLC) and is considered as a leading cause for the unsatisfactory prognosis of patients. Although lymphangiogenesis is well-recognized as...
Leming Sun,Hongmei Liu,Yanqi Ye et al.
Leming Sun et al.
Smart nanoparticles, which can respond to biological cues or be guided by them, are emerging as a promising drug delivery platform for precise cancer treatment. The field of oncology, nanotechnology, and biomedicine has witnessed rapid prog...
Immunity-and-matrix-regulatory cells enhance cartilage regeneration for meniscus injuries: a phase I dose-escalation trial [0.03%]
针对半月板损伤的软骨再生增强型免疫调节细胞和基质调控细胞I期剂量递增试验
Liangjiang Huang,Song Zhang,Jun Wu et al.
Liangjiang Huang et al.
Immunity-and-matrix-regulatory cells (IMRCs) derived from human embryonic stem cells have unique abilities in modulating immunity and regulating the extracellular matrix, which could be mass-produced with stable biological properties. Despi...
The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID [0.03%]
长期新冠的长期健康结局、病理生理机制及多学科管理
Jingwei Li,Yun Zhou,Jiechao Ma et al.
Jingwei Li et al.
There have been hundreds of millions of cases of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the growing population of recovered patients, it is crucial to under...
Dietary reprogram of macrophages for cell competition: a promising strategy for malignant cancer control [0.03%]
通过饮食再编程巨噬细胞进行细胞竞争：恶性癌症控制的潜在策略
Jian Chen,Zhaoliang Su,Guangchuan Wang
Jian Chen
RNA modification in cardiovascular disease: implications for therapeutic interventions [0.03%]
心血管病中的RNA修饰及其治疗意义
Cong Wang,Xuyang Hou,Qing Guan et al.
Cong Wang et al.
Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically...
Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study [0.03%]
卡瑞利珠单抗（PD-1抑制剂）联合阿帕替尼（VEGFR-2抑制剂）和肝动脉灌注化疗治疗巴塞罗那临床肝癌分期C期的肝细胞癌：Ⅱ期研究
Tian-Qi Zhang,Zhi-Jun Geng,Meng-Xuan Zuo et al.
Tian-Qi Zhang et al.
Hepatic arterial infusion chemotherapy (HAIC) using a combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promise for hepatocellular carcinoma (HCC) patients classified under Barcelona Clinic Liver Cancer (BCLC) stag...
Unmasking metabolic dependencies in pancreatic cancer: aberrant polyamine synthesis as a promising new therapeutic target [0.03%]
揭示胰腺癌代谢特征：异常多胺合成作为新的治疗靶点
Gerrit Wolters-Eisfeld,Thilo Hackert,Cenap Güngör
Gerrit Wolters-Eisfeld
Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma [0.03%]
前期CD8⁺T细胞的特征决定了其在弥漫性大B细胞淋巴瘤患者中的CAR-T疗效
Yao Wang,Chuan Tong,Yuting Lu et al.
Yao Wang et al.
Although chimeric antigen receptor (CAR) T cells have become an important treatment option for patients with relapsed/refractory B-cell malignancies, more than 60% of patients with diffuse large B-cell lymphoma (DLBCL) treated with CAR-T ce...
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A [0.03%]
基于CDK4/CDKN2A的mRNA表达用于评估帕博西尼在软组织肉瘤中疗效的II期临床试验
Javier Martin-Broto,Jeronimo Martinez-Garcia,David S Moura et al.
Javier Martin-Broto et al.
Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors demonstrated activity in terms of progression-free survival (PFS) in advanced dedifferentiated liposarcoma (DD-LPS), a sarcoma with CDK4 amplification. CDK4 overexpression is by far more ...